New Logo

 

OUR MISSION

"The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives."

 

The U.S. Food and Drug Administration (FDA) has approved Valtoco┬« (diazepam nasal spray). This is a new seizure medicine designed to treat periods of frequent seizures or cluster seizures that are distinct from the person’s usual seizure pattern. The term “rescue therapy” or “rescue medicine” is usually used to describe this type of medicine.

-- Valtoco is a nasal spray that can be given easily outside of a medical setting by non-medical people.

-- It is approved as an acute treatment, which means that the medicine is given at the time of the seizures or during periods of frequent seizures. It is not used as a daily seizure medicine or in place of daily seizure medicines.

-- Valtoco can be used in children age 6 and over and in adults with epilepsy.

-- This rescue therapy uses a new technology that allows the diazepam to be absorbed consistently through the nose.

-- Valtoco (diazepam nasal spray) is a benzodiazepine, which is a group of drugs that can stop seizures quickly when used as an acute treatment.

Valtoco is only the third rescue therapy approved for epilepsy. These medicines offer a way to prevent seizure emergencieshospitalizations, and early death in people who are prone to seizure emergencies.

"Valtoco represents an important treatment option for people 6 years and older with break-through clusters of seizures. While rescue therapies that are easy to use are needed by people of all ages, they are especially helpful for children with epilepsy." - Elaine Wirrell MD

The Epilepsy Foundation is working with our partners to expand awareness and practices of rescue therapies for the epilepsy community. Stay tuned for more information!

 

Authored by: Patty Osborne Shafer RN, MN on 1/2020, Reviewed by: Kamil Detyniecki MD on 1/2020